Related Experiment Video
Updated: Feb 12, 2026

Bridging the Technology Divide in the COVID-19 Era: Using Virtual Outreach to Expose Middle and High School Students to Imaging Technology
Published on: September 28, 2022
Complement 3 Glomerulopathy Revisited: Bridging Pathogenesis and Therapy in the New Era
Federico Yandian1, Fernando C Fervenza2, Fernando Caravaca-Fontán3
1Department of Nephrology, Hospital de Clínicas "Dr. Manuel Quintela", Montevideo, Uruguay.
Insights
Complement 3 glomerulopathy is a rare kidney disease. New treatments offer hope, but knowledge gaps remain for managing this complex condition and preventing kidney failure.
Area of Science:
- Nephrology
- Immunology
- Genetics
Background:
- Complement 3 glomerulopathy (C3G) is a rare, heterogeneous kidney disease.
- Characterized by abnormal complement component deposition in glomeruli, leading to inflammation and kidney function decline.
- Current treatments are limited, with high rates of kidney failure and post-transplant recurrence.
Purpose of the Study:
- To review the heterogeneity of C3G.
- To examine emerging therapeutic strategies.
- To highlight advancements in managing C3G.
Main Methods:
- Literature review of C3G pathophysiology, genetics, and treatment trials.
- Analysis of current therapeutic options and their outcomes.
- Discussion of knowledge gaps and future directions.
Main Results:
- C3G exhibits significant heterogeneity in pathophysiology, with genetic variants and autoantibodies playing roles.
- Despite limited current treatments, recent clinical trials show promising results.
- Significant knowledge gaps persist in understanding and managing C3G.
Conclusions:
- C3G management requires addressing its heterogeneous nature.
- Emerging therapies offer potential for improved patient outcomes.
- Further research is crucial to overcome knowledge gaps and optimize C3G treatment.
Abstract:
Complement 3 glomerulopathy is a rare and highly heterogeneous complement-mediated kidney disease characterized by the aberrant deposition of complement components in the glomeruli, triggering inflammation and contributing to progressive kidney function impairment. Despite recent advancements in understanding complement 3 glomerulopathy pathophysiology, therapeutic options remain limited. Current treatments often fail to prevent poor outcomes, with 30-50% of adult patients progressing to kidney failure and high rates of disease recurrence following kidney transplantation. Genetic studies have revealed that variants in complement regulators and effectors contribute to disease susceptibility in a subset of patients, although autoantibody-driven mechanisms account for most cases. Encouraging results from recent clinical trials provide hope for improving the overall prognosis of this entity, yet critical knowledge gaps persist. This review explores the heterogeneity of complement 3 glomerulopathy and examines the emerging therapeutic landscape, highlighting advancements in the management of this complex condition.
Related Concept Videos
Design Example: Strain Gauge Bridge or Wheatstone Bridge
Complement System
Wheatstone Bridge
Thus, for accurate resistance measurements, a...
Bridge rectifier
Operationally, the bridge rectifier allows current flow through two of its diodes during each...
Complementation Tests
Organisms heterozygous for different mutations are crossed pairwise in all combinations. If present on different genes, the mutations can complement each other by providing the missing...
Cross-bridge Cycle

